CompletedInterventionalPhase 1Last updated Dec 11, 2018

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome

Overview

ClinicalTrials.gov ID: NCT02614716
Lead Sponsor: Eli Lilly and CompanyINDUSTRY
Brief Summary: The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.
Study Type

Status

Overall Status: Completed
Start Date: Dec 10, 2015Actual
Primary Completion Date: Sep 5, 2018Actual
Completion Date: Sep 5, 2018Actual

Study Record Dates

First Submitted: Nov 24, 2015
First Submitted that Met QC Criteria: Nov 24, 2015
First Posted: Nov 25, 2015Estimated
Last Update Submitted that Met QC Criteria: Dec 10, 2018
Last Update Posted: Dec 11, 2018Actual
Last Verified: Dec 2018

NCT03736772Completed

A Study of LY3090106 in Japanese and Caucasian Healthy Participants

NCT04700280Terminated

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

NCT07737743Not yet recruiting

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT02896868Completed

A Study of LY3041658 in Participants With Skin Diseases

NCT03933943Completed

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

NCT02775916Completed

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome